- About Us
- New: HIAC Particle Sizing
- New: Cytotoxic Contaminants Analysis
- Foreign Particulate Analysis
- Pharmaceutical Analysis
- Materials Analysis
- Medical Device Analysis
- MDI & DPI Drug Development
- Criminal Forensic Analysis
- Automated Particle Sizing and Identification Services
- Glass Delamination
- Instrumentation & Techniques
- News & Events
- Contact Us
Home / Articles & Publications
Articles & Publications
Discover the latest articles and publications pertaining to Gateway Analytical.
By Rebekah Byrne on March 27, 2015
Foreign particulate matter in drug products is a common problem in the pharmaceutical industry that can have major impacts on pharmaceutical companies, from both financial and safety aspects. […]
Monitoring Degree of Agglomeration in Aqueous Suspensions Subjected to Various Environmental Conditions by Raman Imaging
By Admin on June 17, 2014
Outsourcing the development and manufacturing of generic drug products is a very common strategy in today’s current global market. Because of this, some of the biggest generic manufacturers of orally inhaled and nasal drug products (OINDPs) are located overseas. As a result, evaluating out-of-specification issues, establishing batch-to-batch equivalency, addressing the stability of the products during scale-up, long-term storage, and shipping in varying environmental conditions has become of paramount importance for the industry and regulating agencies around the world.
By Admin on November 1, 2013
Contamination in drug products is a common problem in the pharmaceutical industry that can have major impacts on pharmaceutical companies, from both financial and safety aspects. Inhalable drug products are unique with regards to the affects of contamination, due to enduse design.
By Oksana Olkhovyk on December 13, 2012
Since the approval of the Seretide (Advair) fluticasone/salmeterol dry powder inhaler in 1999, inhaled therapies that combine a bronchodilator, often a longacting beta agonist (LABA), with a maintenance drug, usually an inhaled corticosteroid (ICS), have taken over a large portion of the asthma and COPD markets. And, increasingly, a long-acting muscarinic antagonist (LAMA) is being added to LABA/ICS formulations to create triple therapy combinations.
By Oksana Olkhovyk on December 11, 2012
One of the most promising trends in inhaled therapies over the past few years is the creation of particles that contain multiple active ingredients. Some studies have suggested that two, or even three, APIs deposited in the same location in the lung may have a synergistic effect.